Opioid Use Disorder (OUD) Treatment Market Analysis by Growth, Trends and Forecast (2024–2032) | UnivDatos
According to the UnivDatos Market Insights Analysis, an increase in drug awareness campaigns & associated preventive programs and increasing consideration of buprenorphine patches across the globe will drive the global scenario of the opioid use disorder (OUD) treatment market. As per their “Opioid Use Disorder (OUD) Treatment Market” report, the global market was valued at ~USD 3.2 billion in 2023, growing at a CAGR of about 8.1% during the forecast period from 2024-2032 to reach USD billion by 2032. North America, especially the United States and Canada, has witnessed a rising incidence of opioid use and overdose, which is likely to enhance the necessity of treatment for OUD. Health awareness and early diagnosis of the diseases have been checked and those affected have been treated for OUD. The general improvement in the number of patients seeking OUD treatment in tandem with policy support and improvements in OUD treatment and healthcare delivery will continue to fuel the growth of the North American OUD treatment market. Here’s a detailed overview:
Expanded Treatment Options: The advancement in newer medications for treatment has included new formulations like; buprenorphine prolonged-release and new opioid agonist treatment therapies. New developments are more evidence-based behavioral therapies like Cognitive Behavioral Therapy (CBT) and contingency management have enhanced treatment effectiveness.
Regulatory and Policy Changes: Governments of both countries have made efforts to increase the accessibility of treatment for OUD within their countries through increased funding and support of programs. Constant advancement in medical science and an ever-evolving list of newly approved treatments and alterations to previously existing treatments give more opportunities.
Increased Funding and Investment: Financial commitment and investment in OUD treatment and research from the federal and state governments in the U. S. as well as provincial governments in Canada. Pharmaceutical industries and venture capital invested in the development of new treatments and new markets.
Growth of Telemedicine: Availability and utilization of telehealth technology have increased the probability of people seeking OUD treatment since they do not require face-to-face contact to receive the treatment. As the patient has access to the doctor without having to travel physically, it becomes easier to ensure patients stick to their treatment programs.
Expansion of Naloxone Availability: Assistance from community-based treatment agencies, greater availability and distribution of naloxone, an opioid overdose reversal medication, and engagement in other health and welfare service provision offers increased support to harm reduction. These have resulted in policies that made naloxone more easily available in the market.
Public Awareness and Education: Social mobilization has ensured that OUD and the need for treatment have been publicized through campaigns and education advertisements. The increased emphasis on training healthcare providers in identifying and managing patients with OUD has led to better outcomes.
Integration of Care Models: Pharmacotherapy complemented with behavioral and social support has been established to be more effective compared to pharmacotherapy alone. Providing treatment to OUD with other mental disorders has been generalized to extensive treatment plans.
Market Dynamics and Competition: With advancements in technology, new therapies are being developed as well as new approaches to treatment hence there is competition and expansion. There is both growth of generic and biosimilar drugs in the treatment of OUD which has expanded market reach and cost.
Data and Research: Continuing research and trials at North American institutions aim at refining the approaches and finding novel therapies. Research findings from the outcome studies are gradually influencing the courses of action and interventions being taken for adopting better treatment interventions.
Recent Advancements in North America
In July 2024, the Food and Drug Administration launched a new educational program called “Prescribe with Confidence” that aims to help providers identify and treat opioid use disorder.
In April 2022, Pear Therapeutics launched a program to offer digital therapeutic users access to a telehealth provider. Boston-based Pear’s program offers patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a telehealth provider through its “find a provider tool,” as well as in-person care options.
